Biofrontera Inc. to Report Q4 and Full Year 2025 Results

Biopharmaceutical company to host conference call on March 19, 2026

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Biofrontera Inc., a biopharmaceutical company specializing in photodynamic therapy, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after the U.S. market close on Thursday, March 19, 2026. The company will host a conference call the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.

Why it matters

Biofrontera's financial performance and business updates are closely watched by investors and analysts as the company continues to develop and commercialize its photodynamic therapy products, including Ameluz, for the treatment of actinic keratosis and other dermatological conditions.

The details

Biofrontera will report its Q4 and full year 2025 financial results after the U.S. market close on March 19, 2026. The company will then host a conference call at 10:00 a.m. ET the same day to discuss the results and provide a business update. Biofrontera is a U.S.-based biopharmaceutical company that specializes in photodynamic therapy for dermatological conditions.

  • Biofrontera will report Q4 and full year 2025 financial results after the U.S. market close on Thursday, March 19, 2026.
  • Biofrontera will host a conference call at 10:00 a.m. ET on Thursday, March 19, 2026 to discuss the results and provide a business update.

The players

Biofrontera Inc.

A U.S.-based biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) products, including the drug-device combination Ameluz® with the RhodoLED® lamp series for the treatment of actinic keratosis.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching Biofrontera's Q4 and full year 2025 financial results and business update on March 19, 2026 for insights into the company's continued development and commercialization of its photodynamic therapy products.

The takeaway

As a biopharmaceutical company focused on photodynamic therapy for dermatological conditions, Biofrontera's financial performance and business progress are important indicators of its ability to bring innovative treatment options to market and meet the needs of patients.